2025 HMTRC Workshop
Photo credits 2025 HMTRC Workshop: fallfoto, Elisabeth Fall 2025
The April 2025 Hyperpolarized Carbon-13 MRI Technology Development Workshop includes lectures, hands-on training and discussions on dissolution DNP methodology, polarizer instrumentation, MR Sequence and Acquisitions, Pre-clinical HP Chemistry Preps, Human HP Investigational Dose Formulation & Production, Clinical Translation Methods, Clinical Trial Research, and Analysis & Display Software.
View Agenda
2025 Workshop Video Presentations
Click the links below to view released presentations from the 2025 Workshop:
Day 1:
Center TR&D Presentations
8:00 AM - 9:00 AM
- Welcome & Introductions: Dr. Dan Vigneron PhD, HMTRC Director & Dr. Christopher Hess MD, PhD, Chair of Radiology & Biomedical Imaging
- Hyperpolarized C-13 MRI Clinical Translation Update: Dr. Zhen Jane Wang MD, HP Medical Director
- TR&D1: Technology Development for Polarizer and Detector Instrumentation: Drs. Jeremy Gordon PhD & Duy Dang PharmD
- TR&D2: Development of Novel Hyperpolarized (HP) MR Molecular Imaging Probes Tested in Realistic Preclinical Models and Correlative Science Studies: Drs. Renuka Sriram PhD & John Kurhanewicz PhD
- TR&D3: Acquisition and Analysis Methods for Hyperpolarized MR Data: Drs. Peder Larson PhD & Duan Xu PhD
Day 1:
Plenary Presentations
9:15 AM - 11:15 AM
- Dr. Chris Laustsen PhD, Aarhus University: Cysts, Cells, and Carbon-13: Rethinking PKD Monitoring with Hyperpolarized MRI
- Dr. Gigin Lin MD PhD, Chang Gung Memorial Hospital, Taiwan: Hyperpolarized Carbon-13 MRI in Cancer Immunotherapy
- Dr. Shonit Punwani MD PhD, University College London, Consensus Recommendations for Hyperpolarized [1-13C]pyruvate MRI Multi-center Human Studies
- Dr. Jae Mo Park PhD, University of Texas Southwestern Medical Center: Characterizing Mitochondrial Metabolism in Humans with Fatty Liver
- Dr. Stephen Lai MD PhD, UT MD Anderson Cancer Center: Metabolic Imaging of Treatment Response in Head and Neck Cancers
- Dr. Damian Tyler PhD, University of Oxford, UK: A Year in Oxford Reflections on Research
Day 1:
Plenary Presentations
3:45 PM - 5:00 PM
- Dr. Ivan de Kouchkovsky MD, UCSF: Emerging Clinical Applications of Hyperpolarized C-13 MRI in Prostate Cancer
- Dr. Matthew Merritt PhD, University of Florida: Pyruvate Shunting in Acinar Cells in Type I Diabetes
- Dr. Catriona Rooney PhD, NVision Imaging Technologies GmbH: POLARIS Preclinical: From development to deployment
- Dr. Andrea Capozzi PhD, POLARIZE: dDNP Exotica
Day 1:
Keynote Presentations
5:00 PM - 6:00 PM
- Dr. Sabrina Ronen PhD, UCSF: Hyperpolarized C-13 MRS – Translatable Preclinical Studies for Brain Tumors
- Dr. John Kurhanewicz PhD, UCSF: Evolving Clinical Applications of Hyperpolarized C-13 MRI in Prostate Cancer: Current Status and Next Steps
Day 2: Plenary Presentations
9:30 AM - 10:30 AM
- Dr. James Kempf PhD, Bruker Scientist: High-throughput d-DNP for MRI & NMR
- Dr. Titus Lanz PhD, RAPID Biomedical GmbH: RF Coils for Human Application in Hyperpolarized C-13 MFI
- Dr. Kayvan Keshari PhD, Memorial Sloan Kettering Cancer Center, NY: Metabolic Engineering to Fuel Cell-based Therapy
Day 2:
Plenary Presentations
1:00 PM - 3:00 PM
- Dr. Maria Roselle Abraham MD, UCSF: Hyperpolarized C-13 Pyruvate MRI for Cardiac Metabolic Phenotyping
- Dr. Mathilde Hauge Lerche PhD, Technical University of Denmark: Multi Phase Imaging with N-15 Hyperpolarized Betaine
- Dr. Irene-Marco Rius PhD, IBEC, Barcelona, Spain: Hyperpolarization-enhanced NMR and MRI Methods for Tissue Engineering Applications
Day 2:
Plenary Presentations
3:15 PM - 4:45 PM
- Dr. Rachel Katz-Brull PhD, Hadassah, Hebrew University, Jerusalem, Israel: Real-time in-cell Metabolic Fluxes in the Brain. What can we learn from ex vivo studies?
- Dr. Redha Boubertakh PhD, National Heart Centre Singapore, PhD: Initial Hyperpolarised C-13 Clinical Experience at NHCS
- Dr. Min Wu PhD, West China Hospital, Sichuan University: Hyperpolarized C-13 MR Platform in West China Hospital
- Dr. Yaewon Kim PhD, UCSF: Translation of Hyperpolarized [13C. 15N2]Urea MRI for Novel Human Brain Perfusion Studies
